United Conference of Generic Medicine, Vaccines and Biosimilars

9 April 2021: Zina Kobbi CEO of AREMA will be the Keynote Speaker on the virtual conference “United Conference of Generic Medicine, Vaccines and Biosimilars” to talk about “Biosimilar Regulatory and Development Considerations in North African Countries.”


New Bioequivalence guideline Morocco

New guideline of bioequivalence was recently implemented in Morocco by the drug agency, Ministry of Health the link to the document: .

COVID 19 African Situation

Africa must "wake up" to the coronavirus threat and prepare for the worst, the head of the World Health Organization (WHO) DrTedros has said! Due to economic conditions, overcrowding and poor healthcare system many people across Africa feel vulnerable. The Africa Center for Disease Control and Prevention said Thursday that until now 46 out of 54 African countries have reported cases of Covid-19. Africa seems to be the continent's Coronavirus challenge! .

Medical devices Burkina Fasso

News regulation and requirements for medical devices dossier preparation for registration in Burkina Fasso .

SFDA New regulation of marketing exclusivity

News of Saudi Food and Drug Authority June 2019: “regulation of marketing exclusivity” : this new procedure aims to promote the availability of the important pharmaceutical products in Saudi Arabia, “marketing exclusivity” is granted for a maximum two companies per product for specific period. SFDA publish the list of the pharmaceutical products that are eligible for marketing exclusivity. .

Partnership between Europe and Africa for clinical trials

Le partenariat entre l’Europe et les pays en voie de développement pour les essais cliniques (EDCTP) accorde un financement de 10 millions d’euros sur cinq ans pour le projet « WANECAM 2 » Cette subvention va soutenir les essais cliniques en Afrique sur une nouvelle combinaison antipaludique, KAF156 (ganaplacide) et luméfantrine, à prise unique quotidienne. Le composé KAF156 a démontré qu’il avait le potentiel de traiter le paludisme résistant et pouvait être administré sous la forme d’une dose unique. La subvention contribuera également à construire et renforcer les capacités de recherche dans les quatre pays participants : Burkina Faso, Gabon, Mali et Niger. .

20ème Réunion Ordinaire de l’Assemblée des Ministres de la Santé de la CEDEAO

La 20ème Réunion Ordinaire de l’Assemblée des Ministres de la Santé de la CEDEAO (AMS) aura lieu du 29 avril au 3 mai 2019 à Cotonou en République du Bénin. L'Assemblée des Ministres de la Santé de la CEDEAO (AMS) est un événement annuel important pour la région de la CEDEAO pour la prise de décision dans le domaine de la santé. Les Pays concernés: Bénin Burkina Faso Cabo Verde Côte d'Ivoire Gambia (The) Ghana Guinée Guiné-Bissau Liberia Mali Niger Nigeria Sénégal Sierra Leone Togo .

AREMA New services

New : AREMA as a company specialized in Regulatory Affairs, registration & business development opportunities in Africa (17 countries), enlarge alliances and services and offer now regulatory affairs and registration in CIS countries (12 countries) : Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Mongolia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan. For more information contact us at: .


Discover our new service and offer for eCTD! .

AREMA at CPHI WORLDWIDE from 9 to 11 October

AREMA will be visiting CPHI WORLDWIDE (from 9 to 11 October). If you wish to meet AREMA representative and know more about our services , please contact us directly at: to book an appointment. .

WHO Pilot Procedure for Prequalification of Rituximab / Trastuzumab

05 July 2018: WHO launched a pilot project for prequalifying biotherapeutic medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries. To that end, WHO is inviting manufacturers to submit applications for prequalification of two biotherapeutic products: Rituximab (used principally to treat non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia), and Trastuzumab (used to treat breast cancer) and their corresponding similar biotherapeutic products. For more information: .

SFDA, Good Manufacturing Practice for Blood Establishments.

SFDA (Saudi Food & Drug Authority) adopted on 06 June 2018 , Good Manufacturing Practice for Blood Establishments. The purpose of this document is to provide guidance for GMP-inspectors and useful information for blood establishments relating to the collection, preparation, storage, dispatch, quality control and quality assurance of blood and blood components. For more information here is the Link to the complete document: .

FDA approves first biosimilar to Neulasta (pegfilgrastim)

04 June 2018: FDA approves first biosimilar to Neulasta (pegfilgrastim) of Mylan GmbH. This porduct helps to reduce the risk of infection during cancer treatment . The FDA’s approval of Fulphila is based on review of evidence that included extensive structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity data, and other clinical safety and effectiveness data that demonstrates Fulphila is biosimilar to Neulasta. Fulphila has been approved as a biosimilar, not as an interchangeable product. .

African Economic Forum

Tunisia Hosts African Economic Forum on 24 and 25 April 2018 .